Literature DB >> 21291357

Retinal ganglion cell gene therapy and visual system repair.

Mats Hellström1, Alan R Harvey.   

Abstract

Recent clinical trials have shown that the use of replication deficient viral vectors to genetically modify cells in the retina can be of therapeutic benefit in the treatment of certain inherited degenerative conditions that compromise photoreceptor, and hence visual, function. This review is focussed primarily on the use of recombinant adeno-associated viral (rAAV) vectors to target neurons in inner retina, specifically retinal ganglion cells (RGCs). Genetic modification of RGCs may be of value in various ophthalmic conditions in which there is documented loss of RGCs or damage to their centrally projecting axons. Such conditions include glaucoma, optic neuritis, vascular disruption or trauma, and neurological degenerative conditions such as Alzheimer's disease. Furthermore, because the retina and optic nerve (ON) form part of the CNS, the visual system is a useful experimental model in which to study the molecular and cellular mechanisms that underlie degenerative as well as regenerative responses of adult CNS neurons after injury. Gene therapy studies from a number of laboratories are first reviewed, involving not only rAAV-based treatments but also application of lentiviral and adenoviral vectors. Recent work from our own laboratory is then summarized, in which intravitreal injection of rAAV2 serotype vectors is used to introduce growth promoting genes into injured RGCs. rAAV encoding a secretable form of ciliary neurotrophic factor (CNTF) has proved to be particularly effective in promoting RGC survival and axon regeneration after optic nerve crush or after transection followed by a peripheral nerve autograft. In the latter situation we have found that RGCs and their regenerated axons are maintained for at least 15 months after the initial injury. We have also combined rAAV gene therapy with pharmacotherapy to determine if cAMP elevation and additional intravitreal injections of growth factors can act synergistically with vector-based delivery of growth-promoting genes.

Entities:  

Mesh:

Year:  2011        PMID: 21291357     DOI: 10.2174/156652311794940746

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  28 in total

Review 1.  Optic nerve regeneration in mammals: Regenerated or spared axons?

Authors:  Dietmar Fischer; Alan R Harvey; Vincent Pernet; Vance P Lemmon; Kevin K Park
Journal:  Exp Neurol       Date:  2017-07-14       Impact factor: 5.330

2.  Proceedings of the First International Optogenetic Therapies for Vision Symposium.

Authors:  Peter J Francis; Brian Mansfield; Stephen Rose
Journal:  Transl Vis Sci Technol       Date:  2013-11-21       Impact factor: 3.283

3.  Gene therapy strategies in glaucoma and application for steroid-induced hypertension.

Authors:  Teresa Borrás
Journal:  Saudi J Ophthalmol       Date:  2011-05-08

4.  Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.

Authors:  R F Boyd; S L Boye; T J Conlon; K E Erger; D G Sledge; I M Langohr; W W Hauswirth; A M Komáromy; S E Boye; S M Petersen-Jones; J T Bartoe
Journal:  Gene Ther       Date:  2016-04-07       Impact factor: 5.250

5.  CXCL10 suppression of hem- and lymph-angiogenesis in inflamed corneas through MMP13.

Authors:  Nan Gao; Xiaowei Liu; Jiayin Wu; Juan Li; Chen Dong; Xinyi Wu; Xiao Xiao; Fu-Shin X Yu
Journal:  Angiogenesis       Date:  2017-06-16       Impact factor: 9.596

Review 6.  Mitochondrial disorders and the eye.

Authors:  Nicole J Van Bergen; Rahul Chakrabarti; Evelyn C O'Neill; Jonathan G Crowston; Ian A Trounce
Journal:  Eye Brain       Date:  2011-09-26

7.  P2X7 receptor inhibition increases CNTF in the subventricular zone, but not neurogenesis or neuroprotection after stroke in adult mice.

Authors:  Seong Su Kang; Matthew Phillip Keasey; Theo Hagg
Journal:  Transl Stroke Res       Date:  2013-10       Impact factor: 6.829

8.  Innovation under Regulatory Uncertainty: Evidence from Medical Technology.

Authors:  Ariel Dora Stern
Journal:  J Public Econ       Date:  2016-11-23

9.  Chemokine CCL5 promotes robust optic nerve regeneration and mediates many of the effects of CNTF gene therapy.

Authors:  Lili Xie; Yuqin Yin; Larry Benowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

10.  BDNF treatment and extended recovery from optic nerve trauma in the cat.

Authors:  Arthur J Weber; Christine D Harman
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.